BR0317623A - Escitalopram, composição farmacêutica, e, uso de hidrobrometo de escitalopram - Google Patents

Escitalopram, composição farmacêutica, e, uso de hidrobrometo de escitalopram

Info

Publication number
BR0317623A
BR0317623A BR0317623-1A BR0317623A BR0317623A BR 0317623 A BR0317623 A BR 0317623A BR 0317623 A BR0317623 A BR 0317623A BR 0317623 A BR0317623 A BR 0317623A
Authority
BR
Brazil
Prior art keywords
escitalopram
pharmaceutical composition
hydrobromide
hydrobrometh
citalopram
Prior art date
Application number
BR0317623-1A
Other languages
English (en)
Portuguese (pt)
Inventor
Lawrence Martel
Robert Dancer
Hans Petersen
Peter Ellegaard
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32668635&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0317623(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of BR0317623A publication Critical patent/BR0317623A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Nutrition Science (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
BR0317623-1A 2002-12-23 2003-12-18 Escitalopram, composição farmacêutica, e, uso de hidrobrometo de escitalopram BR0317623A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200202005 2002-12-23
PCT/DK2003/000902 WO2004056791A1 (en) 2002-12-23 2003-12-18 Escitalopram hydrobromide and a method for the preparation thereof

Publications (1)

Publication Number Publication Date
BR0317623A true BR0317623A (pt) 2005-11-29

Family

ID=32668635

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0317623-1A BR0317623A (pt) 2002-12-23 2003-12-18 Escitalopram, composição farmacêutica, e, uso de hidrobrometo de escitalopram

Country Status (32)

Country Link
US (1) US20040167209A1 (enExample)
EP (1) EP1578738B1 (enExample)
JP (2) JP4658613B2 (enExample)
KR (1) KR20050086933A (enExample)
CN (1) CN100349885C (enExample)
AR (1) AR042652A1 (enExample)
AT (1) ATE388947T1 (enExample)
AU (1) AU2003287919B2 (enExample)
BR (1) BR0317623A (enExample)
CA (1) CA2511142A1 (enExample)
CY (1) CY1107451T1 (enExample)
DE (1) DE60319739T2 (enExample)
DK (1) DK1578738T3 (enExample)
EA (1) EA013116B1 (enExample)
EG (1) EG24729A (enExample)
ES (1) ES2298595T3 (enExample)
IL (1) IL169125A0 (enExample)
IS (1) IS2654B (enExample)
ME (1) MEP5808A (enExample)
MX (1) MXPA05005772A (enExample)
MY (1) MY135468A (enExample)
NO (1) NO20053595L (enExample)
NZ (1) NZ540281A (enExample)
PE (1) PE20040924A1 (enExample)
PL (1) PL378275A1 (enExample)
PT (1) PT1578738E (enExample)
RS (1) RS51092B (enExample)
TW (1) TW200501943A (enExample)
UA (1) UA80170C2 (enExample)
UY (1) UY28148A1 (enExample)
WO (1) WO2004056791A1 (enExample)
ZA (1) ZA200504109B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0317623A (pt) * 2002-12-23 2005-11-29 Lundbeck & Co As H Escitalopram, composição farmacêutica, e, uso de hidrobrometo de escitalopram
US20050137255A1 (en) * 2002-12-23 2005-06-23 H. Lundbeck A/S Crystalline escitalopram hydrobromide and methods for preparing the same
NZ549100A (en) * 2004-03-05 2010-02-26 Lundbeck & Co As H Crystalline composition containing escitalopram oxalate
TWI358407B (en) 2005-06-22 2012-02-21 Lundbeck & Co As H Crystalline base of escitalopram and orodispersibl
US7834201B2 (en) 2005-06-22 2010-11-16 H. Lundbeck A/S Crystalline base of escitalopram and orodispersible tablets comprising escitalopram base
US20070112075A1 (en) * 2005-10-14 2007-05-17 Forest Laboratories, Inc. Stable pharmaceutical formulations containing escitalopram and bupropion
EP1954257A4 (en) * 2005-10-14 2009-05-20 Lundbeck & Co As H METHOD FOR TREATING DISORDERS OF THE CENTRAL NERVOUS SYSTEM WITH A LOW-DOSED COMBINATION OF ESCITALOPRAM AND BUPROPION
TW200812993A (en) * 2006-05-02 2008-03-16 Lundbeck & Co As H New uses of escitalopram
JP5501615B2 (ja) * 2006-07-11 2014-05-28 田辺三菱製薬株式会社 モルホリン化合物の塩
WO2008059514A2 (en) * 2006-07-31 2008-05-22 Cadila Healthcare Limited Process for preparing escitalopram
FR3006594A1 (fr) * 2013-06-11 2014-12-12 Sorin Crm Sas Microsonde implantable de detection/stimulation incorporant un agent anti-inflammatoire
CN108976188B (zh) * 2017-06-05 2022-12-06 上海奥博生物医药股份有限公司 一种艾司西酞普兰双羟萘酸盐新的制备方法
RU2020111694A (ru) * 2017-10-09 2021-11-12 Тева Фармасьютикал Индастриз Лтд. Новые соли и твердые формы эсциталопрама
EP4277661A1 (en) 2021-01-18 2023-11-22 Anton Frenkel Pharmaceutical dosage form

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US34712A (en) * 1862-03-18 James h
GB1526331A (en) * 1976-01-14 1978-09-27 Kefalas As Phthalanes
GB8419963D0 (en) * 1984-08-06 1984-09-12 Lundbeck & Co As H Intermediate compound and method
GB8814057D0 (en) * 1988-06-14 1988-07-20 Lundbeck & Co As H New enantiomers & their isolation
ATE230738T1 (de) * 1998-10-20 2003-01-15 Lundbeck & Co As H Verfahren zur herstellung von citalopram
AR021155A1 (es) * 1999-07-08 2002-06-12 Lundbeck & Co As H Tratamiento de desordenes neuroticos
PT1298124E (pt) * 1999-10-25 2007-05-31 Lundbeck & Co As H Método para a preparação de citalopram
US6977306B2 (en) * 2000-05-02 2005-12-20 Sumitomo Chemical Company, Limited Citalopram hydrobromide crystal and method for crystallization thereof
JP2002020379A (ja) * 2000-05-02 2002-01-23 Sumika Fine Chemicals Co Ltd シタロプラム臭化水素酸塩の結晶およびその結晶化方法
IES20010693A2 (en) * 2000-08-10 2002-07-10 Lundbeck & Co As H Pharmaceutical composition containing citalopram
WO2002046340A1 (de) * 2000-12-04 2002-06-13 Dr. Frische Gmbh Verfahren zur herstellung von fettsaüreestern
MXPA03008777A (es) * 2001-05-01 2004-02-12 Lundbeck & Co As H El uso de escitalopram enantiomericamente puro.
AR034612A1 (es) * 2001-06-25 2004-03-03 Lundbeck & Co As H Proceso para la preparacion del citalopram racemico y/o del s- o r-citalopram mediante la separacion de una mezcla de r- y s-citalopram
BR0317623A (pt) * 2002-12-23 2005-11-29 Lundbeck & Co As H Escitalopram, composição farmacêutica, e, uso de hidrobrometo de escitalopram
US20050174782A1 (en) * 2003-03-25 2005-08-11 Chapman Leonard T. Flashlight

Also Published As

Publication number Publication date
AR042652A1 (es) 2005-06-29
ATE388947T1 (de) 2008-03-15
DE60319739T2 (de) 2008-07-17
JP4658613B2 (ja) 2011-03-23
EA013116B1 (ru) 2010-02-26
WO2004056791A1 (en) 2004-07-08
RS20050487A (sr) 2007-06-04
IS2654B (is) 2010-08-15
AU2003287919A1 (en) 2004-07-14
ZA200504109B (en) 2006-08-30
JP2011037893A (ja) 2011-02-24
KR20050086933A (ko) 2005-08-30
CA2511142A1 (en) 2004-07-08
EP1578738B1 (en) 2008-03-12
PT1578738E (pt) 2008-04-11
DK1578738T3 (da) 2008-06-30
PE20040924A1 (es) 2004-12-11
MY135468A (en) 2008-04-30
AU2003287919B2 (en) 2009-11-12
PL378275A1 (pl) 2006-03-20
EA200501046A1 (ru) 2005-12-29
DE60319739D1 (de) 2008-04-24
CN1726202A (zh) 2006-01-25
ES2298595T3 (es) 2008-05-16
CY1107451T1 (el) 2012-12-19
CN100349885C (zh) 2007-11-21
MXPA05005772A (es) 2005-08-16
TW200501943A (en) 2005-01-16
RS51092B (sr) 2010-10-31
NZ540281A (en) 2008-07-31
MEP5808A (xx) 2010-02-10
JP2006514952A (ja) 2006-05-18
EG24729A (en) 2010-06-21
UY28148A1 (es) 2004-09-30
EP1578738A1 (en) 2005-09-28
IS7848A (is) 2005-05-17
US20040167209A1 (en) 2004-08-26
HK1087708A1 (en) 2006-10-20
NO20053595L (no) 2005-09-05
UA80170C2 (en) 2007-08-27
IL169125A0 (en) 2009-02-11

Similar Documents

Publication Publication Date Title
PA8539901A1 (es) Novedosa sal de succinato de o-desmetil-venlafaxina
BR0317623A (pt) Escitalopram, composição farmacêutica, e, uso de hidrobrometo de escitalopram
BR9713363A (pt) Epotilonas c, d, e e f, preparação e composições
BR0116831A (pt) Composição oral e seu uso
AR021981A1 (es) Composicion farmaceutica para una administracion por via oral destinada a evitar la desviacion de uso en detrimento de un tercero
ES2157993T3 (es) Benzoilguanidinas, su preparacion y su uso en medicamentos.
MEP39108A (en) Pharmaceutical composition
DK1263720T3 (da) Azetidinderivater, fremstilling deraf samt farmaceutiske sammensætninger, der indeholder samme
CR7583A (es) Nueva sal formiato de o-desmetil venlafaxina
BR0109041B1 (pt) composições de policarbonato, uso das mesmas e uso de materiais inorgánicos.
SV2002000776A (es) Nuevas imidazotriazinonas sustituidas ref.lea 34 985-sv
BR9909486A (pt) Compostos calcilìticos
BR0314058A (pt) Composições para cuidados pessoais a base de álcool ramificado
BG101401A (bg) Състави за орално приложение с удължено освобождаване на цисаприд
BR0114814A (pt) Composições compreendendo composto de modafinila e seu uso
BR0213278B1 (pt) composição vedante e seu uso.
BR0008139B1 (pt) composição lubrificante, e, uso de uma composição lubrificante.
BR0114380A (pt) Derivados-1-aminobutan-3-ol-substituìdos
ITRM950273A0 (it) Antagonisti di interluchina-6 umana del tutto incapaci di formare un legame con gp 130, e loro uso per la preparazione di composizioni farmaceutiche.
BR0115856B1 (pt) composição betuminosa, e, uso da composição.
BR0115281A (pt) Composições de n-(metiletilaminocarbonil)-4-(3-metilfenilamino)-3piri dilsulfonamida e oligossacarìdeos cìclicos
CL2004001317A1 (es) Composicion farmaceutica que comprende el antagonista de receptores de progesterona 11b-(4-acetilfenil)-17b-hidroxi-17 alfa-(1,1,2,2,2-pentafluoroetil)-estra-4,9-dien-3-ona y un antiestrogeno puro; y su uso para tratar una enfermedad dependiente de h
BRPI0414732A (pt) piridilacetilenos para uso como radiotraçadores e agentes de imageamento
SE0000303D0 (sv) Novel compounds
YU87501A (sh) Farmaceutski kompleksi

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2144 DE 07/02/2012.